Research advances in the pathogenesis of special venous malformations

References:

[1] Vikkula M,Boon LM,Carraway KL 3rd,et al.Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2[J].Cell,1996,87(7):1181-1190.DOI:10.1016/s0092-8674(00)81814-0.
[2] Shu W,Lin Y,Hua R,et al.Cutaneomucosal venous malformations are linked to the TIE2 mutation in a large Chinese family[J].Exp Dermatol,2012,21(6):456-457.DOI:10.1111/j.1600-0625.2012.01492.x.
[3] Zú?iga-Castillo M,Teng CL,Teng JMC.Genetics of vascular malformation and therapeutic implications[J].Curr Opin Pediatr,2019,31(4):498-508.DOI:10.1097/mop.0000000000000794.
[4] Du Z,Ma HL,Zhang ZY,et al.Transgenic expression of a venous malformation related mutation,TIE2-R849W,significantly induces multiple malformations of zebrafish[J].Int J Med Sci,2018,15(4):385-394.DOI:10.7150/ijms.23054.
[5] Kangas J,N?tynki M,Eklund L.Development of molecular therapies for venous malformations[J].Basic Clin Pharmacol Toxicol,2018,123(Suppl 5):6-19.DOI:10.1111/bcpt.13027.
[6] Isoldi S,Belsha D,Yeop I,et al.Diagnosis and management of children with blue rubber bleb nevus syndrome:A multi-center case series[J].Dig Liver Dis,2019,51(11):1537-1546.DOI:10.1016/j.dld.2019.04.020.
[7] Soblet J,Kangas J,N?tynki M,et al.Blue rubber bleb nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations[J].J Invest Dermatol,2017,137(1):207-216.DOI:10.1016/j.jid.2016.07.034.
[8] Wong XL,Phan K,Rodríguez Bandera AI,et al.Sirolimus in blue rubber bleb naevus syndrome:A systematic review[J]. J Paediatr Child Health,2019,55(2):152-155.DOI:10.1111/jpc.14345.
[9] Yin J,Qin Z,Wu K,et al.Rare germline GLMN variants identified from blue rubber bleb nevus syndrome might impact mTOR signaling[J].Comb Chem High Throughput Screen,2019,22(10):675-682.DOI:10.2174/1386207322666191203110042.
[10] Anwár G,Elma PA,Adib JS,et al.Blue rubber bleb nevus syndrome with multiple cavernoma-like lesions on MRI:a familial case report and literature review[J].Front Neurol,2020,11:176.DOI:10.3389/fneur.2020.00176.
[11] Brouillard P,Ghassibé M,Penington A,et al.Four common glomulin mutations cause two thirds of glomuvenous malformations ( "familial glomangiomas" ):evidence for a founder effect[J].J Med Genet,2005,42(2):e13.DOI:10.1136/jmg.2004.024174.
[12] Esteves M,César A,Baudrier T,et al.A case of familial glomuvenous malformation with report of a novel genetic mutation[J].Int J Dermatol,2019,Sep 4.DOI:10.1111/ijd.14613.
[13] Wetzel-Strong SE,Detter MR,Marchuk DA.The pathobiology of vascular malformations:insights from human and model organism genetics[J].J Pathol,2017,241(2):281-293.DOI:10.1002/path.4844.
[14] Paolacci S,Zulian A,Bruson A,et al.Vascular anomalies:molecular bases,genetic testing and therapeutic approaches[J].Int Angiol,2019,38(2):157-70.DOI:10.23736/s0392-9590.19.04154-3.
[15] Abou-Fadel J,Vasquez M,Grajeda B,et al.Systems-wide analysis unravels the new roles of CCM signal complex (CSC)[J].Heliyon,2019,5(12):e02899.DOI:10.1016/j.heliyon.2019.e02899.
[16] Antognelli C,Trapani E,Delle Monache S,et al.KRIT1 loss-of-function induces a chronic Nrf2-mediated adaptive homeostasis that sensitizes cells to oxidative stress:Implication for cerebral cavernous malformation disease[J].Free Radic Biol Med,2018,115:202-218.DOI:10.1016/j.freeradbiomed.2017.11.014.
[17] Padarti A,Zhang J.Recent advances in cerebral cavernous malformation research[J].Vessel Plus,2018,2:21.DOI:10.20517/2574-1209.2018.34.
[18] Fisher OS,Deng H,Liu D,et al.Structure and vascular function of MEKK3-cerebral cavernous malformations 2 complex[J].Nat Commun,2015,6:7937.DOI:10.1038/ncomms8937.
[19] Zhou Z,Tang AT,Wong WY,et al.Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling[J].Nature,2016,532(7597):122-126.DOI:10.1038/nature17178.
[20] Bergametti F,Denier C,Labauge P,et al.Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations[J].Am J Hum Genet,2005,76(1):42-51.DOI:10.1086/426952.
[21] Lant B,Pal S,Chapman EM,et al.Interrogating the ccm-3 gene network[J].Cell Rep,2018,24(11):2857-68.e4.DOI:10.1016/j.celrep.2018.08.039.
[22] Wang K,Zhou HJ,Wang M.CCM3 and cerebral cavernous malformation disease[J].Stroke Vasc Neurol,2019,4(2):67-70.DOI:10.1136/svn-2018-000195.
[23] Cetinkaya A,Xiong JR,Vargel ?,et al.Loss-of-function mutations in ELMO2 cause intraosseous vascular malformation by impeding RAC1 signaling[J].Am J Hum Genet,2016,99(2):299-317.DOI:10.1016/j.ajhg.2016.06.008.
[24] Vargel I,Calis M,Canter HI,et al.Clinical and molecular study of elmo-2-related massive intraosseous vascular malformations:lessons learned from 25 years of follow-up[J].Ann Plast Surg,2019,83(3):293-299.DOI:10.1097/sap.0000000000001786.
[25] Wang Y,Li H,Li F.ELMO2 association with Gαi2 regulates pancreatic cancer cell chemotaxis and metastasis[J].Peer J,2020,8:e8910.DOI:10.7717/peerj.8910.
[26] Mehawej C,Hoischen A,Farah RA,et al.Homozygous mutation in ELMO2 may cause Ramon syndrome[J].Clin Genet,2018,93(3):703-706.DOI:10.1111/cge.13166.
[27] Beijnen UEA,Saldanha F,Ganske I,et al.Verrucous venous malformations of the hand[J].J Hand Surg Eur Vol,2019,44(8):850-855.DOI:10.1177/1753193419845271.
[28] Boccara O,Ariche-Maman S,Hadj-Rabia S,et al.Verrucous hemangioma (also known as verrucous venous malformation):A vascular anomaly frequently misdiagnosed as a lymphatic malformation[J].Pediatr Dermatol,2018,35(6):e378-e381.DOI:10.1111/pde.13671.
[29] Couto JA,Vivero MP,Kozakewich HP,et al.A somatic MAP3K3 mutation is associated with verrucous venous malformation[J].Am J Hum Genet,2015,96(3):480-486.DOI:10.1016/j.ajhg.2015.01.007.
[30] Nguyen HL,Boon LM,Vikkula M.Vascular anomalies caused by abnormal signaling within endothelial cells:targets for novel therapies[J].Semin Intervent Radiol,2017,34(3):233-238.DOI:10.1055/s-0037-1604296.
[31] Zhang G,Chen H,Zhen Z,et al.Sirolimus for treatment of verrucous venous malformation:A retrospective cohort study[J].J Am Acad Dermatol,2019,80(2):556-558.DOI:10.1016/j.jaad.2018.07.014.